Pyoderma Gangrenosum Clinical Trial
Official title:
Characterizing Pyoderma Gangrenosum Lesion Regression and Remission by IL-36 Receptor Targeting With Spesolimab
The purpose of this research study is to assess the feasibility of using spesolimab in participants with moderate to severe pyoderma gangrenosum. Pyoderma gangrenosum is a rare, inflammatory, autoimmune condition which results in ulceration of skin. The study will also investigate the body's immune response to the spesolimab (when the body detects and defends itself against substances that appear unknown and harmful).
To date, there is no gold standard for treatment of PG. Patients with pyoderma gangrenosum suffer from severe pain and poor quality of life due to frequent dressing changes and disfiguring lesions. More importantly, rapidly progressing ulcers present an important risk for infection, morbidity, and mortality for patients. Spesolimab is humanized antagonistic monoclonal IgG1 antibody that blocks human IL36R signalling and subsequent downstream pro-inflammatory pathways. The IL-36 receptor blocker was recently approved for generalized pustular psoriasis (GPP). The research team hypothesize that targeting IL-36 in refractory, ulcerative postoperative PG may result in regression and resolution of a patient's lesions. There are, at minimum, a total of 14 or 15 visits which will include physical exams, blood testing and infectious disease testing, completing questionnaires, and photographs and assessment of skin affected by PG. Spesolimab will be administered via a 90-minute infusion every 3 or 4 weeks (depending on response at Visit 4) at 8 or 9 Visits during the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03311464 -
A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan
|
Phase 3 | |
| Recruiting |
NCT04901325 -
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
|
Phase 2 | |
| Completed |
NCT00791557 -
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
|
N/A | |
| Terminated |
NCT02318914 -
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
|
Phase 3 | |
| Terminated |
NCT02315417 -
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
|
Phase 3 | |
| Completed |
NCT03137160 -
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
|
Phase 2 | |
| Not yet recruiting |
NCT05984654 -
Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum
|
N/A | |
| Completed |
NCT04895566 -
Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma
|
Early Phase 1 | |
| Withdrawn |
NCT04274166 -
Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
|
Phase 2 | |
| Completed |
NCT01882504 -
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
|
Phase 2 | |
| Withdrawn |
NCT00730717 -
Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum
|
Phase 2 | |
| Completed |
NCT03971643 -
Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
|
Phase 2 | |
| Not yet recruiting |
NCT04792957 -
JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
|
||
| Not yet recruiting |
NCT05821374 -
Deucravacitinib in PG
|
Early Phase 1 | |
| Terminated |
NCT03072953 -
Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum
|
Phase 2 | |
| Recruiting |
NCT05120726 -
A Novel Therapeutic Treatment of Pyoderma Gangrenosum
|
Phase 4 | |
| Withdrawn |
NCT00690846 -
Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum
|
Phase 2 | |
| Completed |
NCT01965613 -
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
|
Phase 2 | |
| Recruiting |
NCT01952275 -
Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
|
N/A | |
| Completed |
NCT01302795 -
Canakinumab for Pyoderma Gangrenosum
|
Phase 2 |